mosaiques diagnostics GmbH, Mellendorfer Str. 7-9, D-30625 Hannover, Germany.
Maturitas. 2011 Mar;68(3):233-44. doi: 10.1016/j.maturitas.2010.11.001. Epub 2010 Nov 26.
In Western societies the process of aging is closely related to the onset of chronic diseases, such as coronary artery disease, diabetic nephropathy or different types of malignancies. Novel biomarkers are urgently needed to assist in managing these diseases. Parallel to technical advancements possibilities for the analysis of the human proteome for biomarkers have recently made considerable progress. In a first part, this article attempts to describe the main proteomic platform technologies, their advantages and disadvantages and will critically review proteomic study design aspects necessary to obtain valuable data, such as choosing suitable clinical specimens, data processing and mining. Physiological age-related alterations in the human proteome have been described and were similar to indolent changes associated with chronic diseases, in particular of the kidneys. Therefore, in a second part this review will introduce several examples for the application of clinical proteomics to aging itself and age-related diseases. Several recent proteome studies with clinically sound designs are available. These performed careful validation in blinded cohorts. It is anticipated that a boost in disease-related proteomic data is expected in the very near future. However, lessons of the past teach the strict adherence to proper technological approaches, appropriate statistics, and large databases to fulfil these high expectations.
在西方社会，衰老过程与慢性疾病的发生密切相关，如冠状动脉疾病、糖尿病肾病或不同类型的恶性肿瘤。迫切需要新的生物标志物来辅助这些疾病的管理。随着技术的进步，人们最近对人类蛋白质组进行分析以寻找生物标志物的可能性取得了相当大的进展。在第一部分中，本文试图描述主要的蛋白质组学平台技术、它们的优缺点，并将批判性地回顾获得有价值数据所需的蛋白质组学研究设计方面，例如选择合适的临床标本、数据处理和挖掘。已经描述了人类蛋白质组中与生理年龄相关的改变，这些改变与慢性疾病（特别是肾脏疾病）相关的缓慢变化相似。因此，在第二部分中，本综述将介绍将临床蛋白质组学应用于衰老本身和与衰老相关的疾病的几个例子。有几个最近的蛋白质组研究具有合理的临床设计。这些研究在盲法队列中进行了仔细的验证。预计在不久的将来，与疾病相关的蛋白质组数据将大幅增加。然而，过去的经验教训告诉我们，必须严格遵守适当的技术方法、适当的统计学方法和大型数据库，以实现这些高期望。
